A prospective case–cohort analysis of plasma metabolites and breast cancer risk

Stevens, Victoria L.; Carter, Brian D.; Jacobs, Eric J.; McCullough, Marjorie L.; Teras, Lauren R.; Wang, Ying

doi:10.1186/s13058-023-01602-x

Breast Cancer Research

Table 3 Summary of metabolites previously replicated, newly replicated, or newly associated with breast cancer risk

From: A prospective case–cohort analysis of plasma metabolites and breast cancer risk

Metabolite	Class	Results from prospective studies^a
		PLCO [5, 6]	SU.VI.MAX [7, 8]	EPIC^b [9]	CPS-II [10]	E3N [11]	CPS-3
Previously replicated^c
Androstenediol (3β,17β) disulfate (1)	Lipid	↑			↑		↑
16α-Hydroxy DHEA 3-sulfate	Lipid	↑			↑		↑
Androstenediol (3β,17β) monosulfate (2)	Lipid	↑			↑		–
PC (O-16:0/18:2)	Lipid			↓(C34:2)	↓		↓
Glutamine	Amino Acid	–	↑	↓	–	↑	↓
New replications^d
Dehydroepiandrosterone sulfate (DHEA-S)	Lipid	↑			–		↑
Androsteroid monosulfate (1)	Lipid	–			↑		↑
Androstenediol (3β,17β) disulfate (2)	Lipid	↑			–		↑
Androstenediol (3β,17β) monosulfate (1)	Lipid	↑			–		↑
Asparagine	Amino Acid	–		↓	–		↓
PC (18:0/18:2)	Lipid	–		↓(C36:2)	–		↓
LysoPE (O-18:0)	Lipid	–			↓		↓
LysoPC (18:2)	Lipid	–		↓	–		↓
Novel Associations^e
Octadecadienoate (C18:2-DC)	Lipid						↓
2-Hydroxysebacate	Lipid						↓
Syringol sulfate	Xenobiotic						↑
3-Methylcatechol sulfate (2)	Xenobiotic						↑
3-Hydroxypyridine glucuronide	Xenobiotic						↑

PLCO Prostate, Lung, Colorectal, and Ovarian Cancer screening trial; SU.VI.MAX Supplémentation en Vitamines et Minéraux Antioxydants cohort: EPIC European Prospective Investigation into Cancer study; CPS-II Cancer Prevention Study II; E3N Etude Epidémiologique auprès de femmes de la MGEN (Mutuelle Générale de l’Education Nationale) cohort; CPS-3 Cancer Prevention Study 3; ref reference
^aThe reference for each cohort from which the results shown were taken are shown below the cohort’s name. The direction of the association reported is shown by the arrow with ↑ indicating a direct association and ↓ indicating an inverse association. The statistical significance of the association is indicated by whether the arrow is or is not in bold print with unbolded arrows corresponding to FDR < 0.20 and bold arrows corresponding to FDR < 0.05. A — indicates that the metabolite was measured in the study but not associated with breast cancer risk. A blank space indicates that the metabolite was not measured in that study
^bThe metabolomics platform used in the EPIC studies provided information on the chain lengths and saturation of the fatty acids in the sn1 and sn2 positions of phospholipids cumulatively rather than individually. Therefore, the lipids found associated in the EPIC studies may include other species in addition to those measured in our study
^cMetabolites were associated with breast cancer risk in two or more previous studies
^dMetabolites associated with breast cancer risk at FDR < 0.20 in this study that replicated previous findings
^eMetabolites associated with breast cancer risk at FDR < 0.20 in this study not measured in any previous study

Back to article page

ISSN: 1465-542X

Contact us

Submission enquiries: journalsubmissions@springernature.com